Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

FDA OKs New Wearable Infusion Device for Parkinson’sThe FDA has approved Onapgo, a new wearable device for adults with advanced Parkinson’s disease that gives a steady dose of apomorphine ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer. In a large cohort of ...

“In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson’s disease, planned for the second quarter of 2025; and further advancement of our ...

is being developed for the management of motor fluctuations and dyskinesia in patients with advanced Parkinson’s Disease. The firm has “high confidence” that SER-252 will at least match the ...

Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced Parkinson's disease. The company plans to launch ONAPGO in the second quarter of 2025.

Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced Parkinson’s disease. The company plans to launch ONAPGO in the second quarter of 2025.